Friday, February 22, 2008; Posted: 04:57 AM
Sign-up for our FREE Stock Alerts at http://www.otcstockexchange.com !
Lithium Technology Corporation (Pink Sheets: LTHU - http://finance.yahoo.com/q?s=LTHU.PK ) (Thu, February 21st, 2008, 8:29am ET) Lithium Technology Corporation ("LTC") announced today that it launched its new product line of high energy density lithium iron phosphate (LiFePO4) cells, the largest cells of their kind in the world. This product line is aimed at answering the need of the electrical vehicle (EV) and the plug in hybrid vehicle (PHEV) markets.
The Company's new product line offers cells ranging from 8 Ah to 40 Ah, which joins the existing high power line, which offers cells ranging from 6 Ah to 35 Ah. The company's complete portfolio of products includes various cell chemistries and large batteries.
"In recent years LTC has been developing and offering battery technology that is unmatched by any other battery power solution on the market," commented Dr. Klaus Brandt, chief executive officer of LTC. "Today we are launching a product line that will complete our offering to the various markets we are targeting. We continue to prove our technical superiority and with the new iron phosphate products we raised the bar again." LTC, a global provider of large lithium-ion rechargeable power solutions, has focused solely on the development and production of large format lithium- ion batteries. LTC has been working closely with the German chemical company Sud-Chemie and its Canadian daughter company Phostech, the sole patent owners of the iron-phosphate technology, to further improve cell materials. This chemistry, coupled with the company's innovative end-to-end manufacturing processes and proprietary design, packaging and assembly techniques, allows LTC to provide high performance cells unmatched by any other product.
LTC's large format technology allows for the development of safer battery systems with a significantly lower number of cells. The weight of the battery is decreased while performance and safety monitoring capabilities are increased. The battery management system (BMS) precisely monitors fewer cells, keeping them in balance for best performance and preventing damage to the battery due to over voltage, under voltage, over temperature and short circuit.
"We developed this product to power the new breed of EV's and for the fleet EV market that has been promoted recently all over the world," concluded Dr. Brandt.
Virtual Ed Link, Inc. (Pink Sheets: VRED - http://finance.yahoo.com/q?s=VRED.PK ) (Thu, February 21st, 2008, 11:00am ET) Virtual Ed Link, Inc., the developer and marketer of the School Safety Management System (SSMS), announced that new Federal legislation is mandating schools and colleges to implement a comprehensive security platform in order for the school to remain eligible for Federal funds and grants.
The Laws S1642 and HR 4137 now require campus compliance for Safety and Crisis Management under strict guidelines. The campus must have a Crisis Management Plan if it is to seek Title IV Funds such as Pell Grants or Perkins Loans. Campuses that do not comply with these new laws face losing Title IV funding and could face other penalties or sanctions.
The VELI SSMS platform, already being implemented at campuses around the country, provides and exceeds all of the requirements currently being mandated in this legislation.
CEO John Bay stated: "This government legislation confirms that our approach is right for the need and right for the time. VELI is setting the standard for security platforms in education. The company continues to review its revenue projections for upward adjustment in light of this new development and the resultant surge in demand that we have already begun to feel."
Virtual Ed Link has made its mantra a "culture of preparedness" that establishes the planning, training, and teaching necessary to help save lives in times of crisis. The demand for VELI's life saving product will continue to grow as campus administrators recognize the VELI System as the standard for school safety.
Aladdin Beverage (Pink Sheets: ADTJ - http://finance.yahoo.com/q?s=ADTJ.PK ) (Wed, February 20th, 2008, 9:52am ET) SKI Distributing in Brooklyn, NY has agreed to represent the Aladdin Beverage portfolio of brands. "We could not be happier with the SKI appointment. Having them and their 30 member sales force support our brands will give us a greater reach into the market as well as allow us to open up some secondary markets like Long Island, Westchester County and Staten Island. This is a huge step forward for us and we are excited to get our brands moving in a big way," states Ted O'Connor, President, Aladdin Beverage.
The brands in the Aladdin portfolio are very attractive for wholesalers to purchase because of the high margins these types of beers command at the wholesale and retail level. "Wholesalers understand that the types of brands Aladdin imports can command margins of over 50% at each tier. Growth for brands like the ones in Aladdin's portfolio, especially organic import brands, is upwards of 40%. This combination of growth and high margins allows everyone to make money and that is a winning combination," states Ted O'Connor.
Advanced Cell Technology, Inc. (OTCBB: ACTC - http://finance.yahoo.com/q?s=ACTC.OB ) (Thu, February 21st, 2008, 12:00pm ET) Advanced Cell Technology, Inc. reported today for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells). The research, described online (ahead of print) in the journal STEM CELLS, signifies a significant step towards the efficient generation of hepatocytes for use in regenerative medicine and drug discovery. Moreover, the research represents another one of Advanced Cell Technology's efforts aimed at the large-scale differentiation of human embryonic stem cells (hESCs) into critical replacement cell types. In addition to demonstrating the efficient generation of hepatocytes in research published today, the company has made significant progress in the generation of retinal pigmented epithelial (RPE) cells to treat retinal degenerative diseases and the generation of hemangioblasts to treat vascular disease as well as to create a large-scale and donorless source of red blood cells and platelets.
Two hallmarks of embryonic stem cells, their versatility and capacity for unlimited self renewal, suggest the cells could serve as a potentially inexhaustible source of cells for replacement therapy. As with other tissues, there is a scarcity of donor livers and hepatocytes, which is compounded by the low recovery and proliferative capacity of adult hepatocytes. In addition to the cells' potential use for the treatment of liver disease, hESC-derived hepatocytes could also provide a valuable model for novel pharmaceutical drug discovery assays as well as new drug metabolism and cytotoxicity screens, particularly because the liver is a major site for detoxification.
"We have established a highly-efficient method for deriving hepatocytes from stem cells that mirrors events in embryonic development," said Robert Lanza, M.D., Chief Scientific Officer at Advanced Cell Technology, Inc. and senior author of the study. "Large scale production of hepatocytes using this method should greatly bolster their applications in basic research, clinical medicine and preclinical drug discovery."
The method reported yielded synchronous populations of hepatocytes that were generated in clinically preferred conditions with minimum use of serum and cell feeders. Highly enriched populations of definitive endoderm (DE) were generated from hESCs and then induced to differentiate along the hepatic lineage by the sequential addition of inducing factors implicated in physiological hepatogenesis. The differentiation process was largely uniform with cell cultures progressively expressing increasing numbers of hepatic lineage markers. The hepatocytes exhibited functional hepatic characteristics such as glycogen storage, indocyanine green uptake and release, and albumin secretion. In an animal model of acute liver injury, the hESC-DE cells differentiated into hepatocytes and successfully repopulated the damaged liver.
"I am delighted with the tremendous progress our scientists are making to generate a variety of important functional cells types and refine our cell differentiation process," stated William M. Caldwell IV, CEO and Chairman of Advanced Cell Technology.
"These cells have the potential to benefit many Americans suffering from serious and potentially life-threatening diseases with few if any alternatives. We are committed to developing new methods to help translate our stem cell technology into the clinic and are seeking partners for some of our newest scientific advances."
Other authors on the paper were Dr. Sadhana Agawal (first author of the study) and Katherine Holton, a senior research associate at Advanced Cell Technology, Inc.
About OTCStockExchange.com
OTCStockExchange.com (OTCS) is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. OTCS is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. OTCS's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. OTCS provides all investors with the latest news, press releases, investment opinions, and research reports for all the companies highlighted on the site. OTCS offers a free financial newsletter. To subscribe or get more information, visit our home page located at http://www.otcstockexchange.com .
We offer many investor relations programs to public companies. To feature a company on our web site or in our daily Newsletter or Mid-Day Stock Alert, please contact Chris Wheeler at 585-330-8514 , or via email at info@otcstockexchange.com .
OTCS's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. OTCS will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
OTCStockExchange.com (OTCS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by OTCS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.otcstockexchange.com or mentioned herein. OTCS has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCS undertakes no obligation to update such statements.
CONTACT: Chris Wheeler, OTCStockExchange.com Tel: +1 585 330 8514 e-mail: info@otcstockexchange.com WWW: http://www.otcstockexchange.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
    |
   |
